NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31

Nasus Pharma Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026

$3.21+0.02 (+0.79%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Nasus Pharma Ltd cash flow statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Stock-Based Compensation	0.45	0.01	0.04
Change in Accounts Payable	0.15	-0.01	-0.12
Operating Cash Flow	-4.92	-0.67	-1.03
Capital Expenditures	-0.01	–	–
Investing Cash Flow	-3.01	–	–
Stock Issued	8.49	–	–
Financing Cash Flow	8.92	0.77	1.06
Foreign Exchange Rate Adjustments	-0.01	0.00	0.01
Net Change in Cash	0.98	0.10	0.04
Free Cash Flow	-4.93	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -0.4%
Net margin: -0.5%
Return on equity, FY2025: 2637.8%

Financial strength

Current ratio: 8.77
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 556.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –